Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review

Bibliography

• Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal 2009;21(67):pe24
   Google Scholar
• Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: Twists and turns in the road to cancer therapy. Clin Cancer Res 2007;13(11):3109-14
   Google Scholar
• Zheng XF, Florentino D, Chen J, TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell 1995;82(1):121-30
   Google Scholar
• Feldman ME, Apsel B, Uotila A, Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009;7(2):e1000038
   Google Scholar
• O'Reilly KE, Rojo F, She Q-B. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8
   PubMed Web of Science ®Google Scholar
• Chresta CM, Davies BR, Hickson I, AZD8055 is a potent, selective and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010;70(1):288-98
   PubMed Web of Science ®Google Scholar
• Bhagwat SV, Crew AP, Gokhale PC, OSI-027, a potent and selective mTORC1/mTORC2 kinase inhibitor is mechanistically distinct from rapamycin [abstract 4487]. AACR; Washington, DC, USA; 2010. p. 101
   Google Scholar
• Liu Y, Wang S, Kessler L, INK128 is a novel, potent and selective TORC1/2 inhibitor with broad oral anti-tumor activity [abstract A40]. AACR Special Conference on Metabolism Cancer; La Jolla, CA, USA; 2009
   Google Scholar
• Knight SD, Adams ND, Burgess JL, Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med Chem Lett 2010;1(1):39-43
   Google Scholar
• LoRusso P, Markman B, Tabernero J, A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients with advanced solid tumors. J Clin Oncol 2009;27(15S): abstract 3502
   Google Scholar
• Richard DJ, Verheijen JC, Zask A. Recent advances in the development of selective, ATP-competitive inhibitors of mTOR. Curr Opin Drug Discov Devel 2010;13(4):428-40
   Google Scholar
• Garcia-Echeverria C. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg Med Chem Lett 2010;20:4308-12
   Google Scholar
• Bhagwat SV, Crew AP. Novel inhibitors of mTORC1 and mTORC2. Curr Opin Investig Drugs 2010;11(6):638-45
   Google Scholar
• Zask A, Kaplan J, Verheijen JC, Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors. J Med Chem 2009;52(24):7942-5
   Google Scholar
• Walker EH, Pacold ME, Perisic O, Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 2000;6:909-19
   PubMed Web of Science ®Google Scholar
• Hayakawa M, Kaizawa H, Moritomo H, Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem Lett 2007;17:2438-42
   PubMed Web of Science ®Google Scholar
• Wyeth LLC. 5,6,7,8-Tetrahydropyrido[4,3-D]pyrimidine compounds, their use as mTOR, PI3, and HSMG-1 kinase inhibitors, and their synthesis. WO120991; 2010
   Google Scholar
• Wyeth LLC. 5,6,7,8-Tetrahydropyrido[3,4-D]pyrimidine compounds, their use as mTOR kinase and PI3 kinase inhibitors, and their synthesis. WO120996; 2010
   Google Scholar
• Genentech, Inc. Pyrimidine compounds, compositions and methods of use. WO014939; 2010
   Google Scholar
• Wyeth LLC. Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors. US098086; 2009
   Google Scholar
• Verheijen JC, Richard, DJ, Discovery of 4-Morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective, ATP-Competitive Inhibitors of mTOR: optimization of the 6-Aryl Substituent. J Med Chem 2009;52:8010-24
   Google Scholar
• Zask A, Verheijen JC, Curran K, ATP-Competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines. J Med Chem 2009;52:5013-16
   PubMed Web of Science ®Google Scholar
• Cellzome Ltd. Pyrimidine derivatives as mTOR inhibitors. WO103094; 2010
   Google Scholar
• Daiichi Sankyo Co., Ltd. Morpholinopurine derivatives. US100130492; 2010
   Google Scholar
• Wyeth LLC. Preparation of imidazolopyrimidine analogs and their use as PI3 kinase and mTOR inhibitors. WO116129; 2008
   Google Scholar
• Centro Nacional de Investigaciones Oncologicas. Imidazopyrazines for use as kinase inhibitors. WO119264; 2010
   Google Scholar
• S*Bio PTE Ltd. Pyrimidine substituted purine compounds as kinase inhibitors. WO114484; 2010
   Google Scholar
• S*Bio PTE Ltd. 8-Substituted-2-morpholino purines for use as PI3K and/or mTOR inhibitors in the treatment of proliferative diseases. WO114494; 2010
   Google Scholar
• Xcovery, Inc. PI3K isoform selective inhibitors. WO005558; 2010
   Google Scholar
• Tyrogenex, Inc. PI3K/mTOR kinase inhibitors. WO056320; 2010
   Google Scholar
• University of Basel. Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes. WO052569; 2010
   Google Scholar
• Venkatesan AM, Dehnhardt CM, Delos Santos E, Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 50-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (PKI-587), a Highly Efficacious Dual Inhibitor. J Med Chem 2010;53:2636-45
   PubMed Web of Science ®Google Scholar
• Wyeth LLC. Pyrimidine compounds, their use as mTOR kinase and PI3 kinase inhibitors, and their synthesis. WO120998; 2010
   Google Scholar
• Zask A, Verheijen JC, Richard DJ, Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors. Bioorg Med Chem Lett 2010;20:2644-7
   Google Scholar
• Verheijen JC, Richard DJ, Curran K, 2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: Optimization of human microsomal stability. Bioorg Med Chem Lett 2010;20:2648-53
   PubMed Web of Science ®Google Scholar
• Richard DJ, Verheijen JC, Yu K, Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kalpha. Bioorg Med Chem Lett 2010;20:2654-7
   Google Scholar
• Intellikine, Inc. Benzoxazole kinase inhibitors and methods of use. WO051042; 2010
   Google Scholar
• Intellikine, Inc. Benzoxazole kinase inhibitors and methods of use. WO051043; 2010
   Google Scholar
• Intellikine, Inc. Benzoxazole kinase inhibitors and methods of use. US190749; 2010
   Google Scholar
• Intellikine, Inc. Benzoxazole kinase inhibitors and methods of use. US184760; 2010
   Google Scholar
• Intellikine, Inc. Preparation of 1H-pyrazolo[3,4-d]pyrimidine compounds as kinase inhibitors and methods of use as therapeutic agents. WO006086; 2010
   Google Scholar
• Intellikine, Inc. and the University of California. MTOR modulators and uses thereof. WO006072; 2010
   Google Scholar
• Schering Corp. Pyrazolo [1,5-a] pyrimidine derivatives as mTOR inhibitors. WO118207; 2010
   Google Scholar
• Signal Pharmaceuticals, LLC. mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway. WO10062571; 2010
   Google Scholar
• Signal Pharmaceuticals, LLC. Heteroaryl compounds, compositions thereof, and methods of treatment therewith. WO08051493; 2008
   Google Scholar
• Daiichi Sankyo Co., Ltd. Imidazopyridin-2-on derivatives. WO10016490; 2010
   Google Scholar
• Signal Pharmaceuticals, LLC. Heteroaryl compounds, compositions thereof, and methods of treatment therewith. WO08051493; 2008
   Google Scholar
• Pfizer Products, Inc. Pyrido (2,3-d) pyrimidinone compounds and their use as PI3 inhibitors. WO032162; 2008
   Google Scholar
• Cheng H, Bagrodia S, Bailey S, Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design. Med Chem Commun 2010;1:139-44
   Web of Science ®Google Scholar
• Liu KKC, Bagrodia S, Bailey S. 4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors. Bioorg Med Chem Lett 2010;20:6096-9
   PubMed Web of Science ®Google Scholar
• Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kalpha and mTOR. WO10039740; 2010
   Google Scholar
• Amgen, Inc. Preparation of indole and benzimidazole compounds as mTOR kinase inhibitors for the treatment of cancer. WO096314; 2010
   Google Scholar
• Amgen, Inc. Heteroaryl compounds as PIKK inhibitors. WO132598; 2010
   Google Scholar
• Amgen, Inc. Preparation of 3-azaheterocyclyl-N-(substituted monocyclyl or bicyclyl)pyridine-2-amines and analogs as PI3 kinase and/or mTOR inhibitors for treating cancers. US273764; 2010
   Google Scholar
• Amgen, Inc. Preparation of substituted imidazopyridines and their analogs as inhibitors of PI3 kinase. WO108074; 2010
   Google Scholar
• Millennium Pharmaceuticals, Inc. and Takeda Pharmaceutical Co. Ltd. Heteroaryls as PI3K and/or mTOR inhibitors and their preparation and use in the treatment of diseases. WO090716; 2010
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. Preparation of thiazolopyridinylacetamide derivatives and analogs for use as PI3K and mTOR kinase inhibitors. WO008847; 2010
   Google Scholar
• Boehringer Ingelheim International GMBH. Thia-triaza-cyclopentazulenes as PI3-kinases inhibitors for the treatment of cancer. WO122071; 2010
   Google Scholar
• Boehringer Ingelheim International GMBH. Preparation of 5-alkynyl-pyridines for treating and/or preventing cancer, infections, inflammatory and autoimmune diseases. WO122069; 2010
   Google Scholar
• Exelixis, Inc. Benzoxazepin-4-(5H)-yl derivatives and their use to treat cancer. WO10118208; 2010
   Google Scholar
• Dana Farber Cancer Institute, Inc. and the Whitehead Institute for Biomedical Research. Soluble mTOR complexes and modulators thereof. WO044885; 2010
   Google Scholar
• Liu Q, Chang JW, Wang, Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J Med Chem 2010;53:7146-55
   PubMed Web of Science ®Google Scholar